Evidence map›Paper›PMID 40290404›Full record

ArticleInfection and drug resistance2025

Establishing Sitafloxacin Epidemiological Cut-off Values (ECOFFs) for Clinical Bacterial Isolates.

Jingjia Zhang, Xue Li, Xinmiao Jia, Yun Li, Bo Zheng, Yunsong Yu, Fupin Hu, Ziyong Sun, Zhongju Chen, Ge Zhang and 9 more

Abstract read
In one paragraph

Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jingjia Zhang *Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Xue Li *Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Xinmiao Jia *Department of Medical Research Center, State Key Laboratory of Complex Severe & Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Yun LiInstitute of Clinical Pharmacology, Peking University, Beijing, People's Republic of China.
Bo ZhengInstitute of Clinical Pharmacology, Peking University, Beijing, People's Republic of China.
Yunsong YuDepartment of Clinical Infectious Diseases, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.
Fupin HuHuashan Hospital of Fudan University, Shanghai, People's Republic of China.
Ziyong SunTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Zhongju ChenTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Ge ZhangDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Wei KangDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Tong WangDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Jin LiDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Haotian GaoDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Qiaolian YiDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Wei YuDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Xiaobing ChuDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Yingchun XuDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Qiwen YangDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To establish the epidemiological cut-off values (ECOFFs) of sitafloxacin against Methods: We collected 2264 clinical isolates from five different labs located in four cities in China. The minimum inhibitory concentrations (MICs) and inhibition zone diameters of sitafloxacin for all isolates were determined by using the broth microdilution method (BMD) and the disk diffusion method according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. MIC ECOFFs were determined using ECOFFinder software, with the 99% calculated ECOFF selected as the initial value. Zone diameter ECOFFs were determined via the visual estimation method. Whole-genome sequencing was performed on Results: Sitafloxacin MICs ranged from 0.002 to 64 mg/L, while inhibition zone diameters ranged from 6 to 45 mm across the nine species. MIC ECOFFs were determined as 0.032, 0.064, 0.125, 0.5, 0.064, 0.125, 0.5, 0.25, and 0.125 mg/L for Conclusion: We established MIC and zone diameter ECOFFs for sitafloxacin against the nine species listed above. The MIC ECOFF for

Indexed as

BMDdisk diffusionECOFFMICsitafloxacinzone diameter

Identifiers

PMID40290404
PMCPMC12034273

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.